Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp continued to hold its position in Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) during the third quarter, Holdings Channel reports. The firm owned 49,800 shares of the company’s stock at the end of the third quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp owned 0.13% of Pacira Pharmaceuticals worth $1,704,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in PCRX. BNP Paribas Arbitrage SA raised its position in shares of Pacira Pharmaceuticals by 111.3% in the third quarter. BNP Paribas Arbitrage SA now owns 3,051 shares of the company’s stock valued at $104,000 after buying an additional 1,607 shares in the last quarter. BlackRock Inc. raised its position in shares of Pacira Pharmaceuticals by 60.5% in the second quarter. BlackRock Inc. now owns 4,007 shares of the company’s stock valued at $135,000 after buying an additional 1,510 shares in the last quarter. US Bancorp DE raised its position in shares of Pacira Pharmaceuticals by 8.5% in the second quarter. US Bancorp DE now owns 5,010 shares of the company’s stock valued at $169,000 after buying an additional 394 shares in the last quarter. Teacher Retirement System of Texas raised its position in shares of Pacira Pharmaceuticals by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 5,184 shares of the company’s stock valued at $175,000 after buying an additional 622 shares in the last quarter. Finally, Westpac Banking Corp raised its position in shares of Pacira Pharmaceuticals by 46.7% in the second quarter. Westpac Banking Corp now owns 5,877 shares of the company’s stock valued at $198,000 after buying an additional 1,870 shares in the last quarter.

Institutional Ownership by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) traded up 2.39% on Tuesday, hitting $32.15. 812,975 shares of the stock were exchanged. The company has a 50-day moving average of $34.12 and a 200-day moving average of $38.64. The stock’s market cap is $1.20 billion. Pacira Pharmaceuticals Inc. has a 12 month low of $30.25 and a 12 month high of $80.25.

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings results on Wednesday, November 2nd. The company reported $0.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.22. Pacira Pharmaceuticals had a negative net margin of 13.37% and a negative return on equity of 1.52%. The company earned $68.40 million during the quarter, compared to analysts’ expectations of $67.16 million. During the same period last year, the company posted $0.32 EPS. Pacira Pharmaceuticals’s revenue was up 10.0% on a year-over-year basis. On average, equities analysts predict that Pacira Pharmaceuticals Inc. will post $0.55 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp Has $1,704,000 Stake in Pacira Pharmaceuticals Inc. (PCRX)” was originally reported by Financial Market News and is the propert of of Financial Market News. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this news story can be viewed at http://www.financial-market-news.com/her-majesty-the-queen-in-right-of-the-province-of-alberta-as-represented-by-alberta-investment-management-corp-has-1704000-stake-in-pacira-pharmaceuticals-inc-pcrx/1209375/.

Several equities analysts have recently weighed in on PCRX shares. Cowen and Company reiterated a “hold” rating on shares of Pacira Pharmaceuticals in a report on Tuesday, September 20th. Zacks Investment Research downgraded shares of Pacira Pharmaceuticals from a “buy” rating to a “sell” rating in a research report on Friday, October 21st. Wedbush reissued an “outperform” rating and set a $109.00 target price on shares of Pacira Pharmaceuticals in a research report on Wednesday, September 21st. BMO Capital Markets raised shares of Pacira Pharmaceuticals from an “underperform” rating to a “market perform” rating and decreased their target price for the stock from $36.00 to $35.00 in a research report on Thursday, October 27th. They noted that the move was a valuation call. Finally, Brean Capital started coverage on shares of Pacira Pharmaceuticals in a research report on Friday, October 7th. They set a “hold” rating for the company. One analyst has rated the stock with a sell rating, five have assigned a hold rating and seven have given a buy rating to the company’s stock. Pacira Pharmaceuticals has an average rating of “Hold” and a consensus price target of $71.18.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control.

5 Day Chart for NASDAQ:PCRX

Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira Pharmaceuticals Inc. (NASDAQ:PCRX).

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.